Literature DB >> 12458154

Altering airway surface liquid volume: inhalation therapy with amiloride and hyperosmotic agents.

Andrew J Hirsh1.   

Abstract

The thin layer of liquid lining the entire respiratory tract is the first line of defense against the continuous insult of inhaled bacteria and noxious chemicals. Many chronic obstructive diseases of the airway may reflect decreased airway surface liquid, which results from imbalances in ion transport and mucus production. Reduction in the thickness of airway surface liquid leads to reduced mucociliary clearance rates, causing mucus accumulation and infection in the airway. In this chapter, two inhalation therapies to replenish airway surface liquid and enhance mucociliary clearance are discussed: (1) aerosolized hyperosmotic agents; and (2) aerosolized sodium channel blockers. The advantages and disadvantages of each therapy are discussed, as well as future directions for improving airway surface liquid volume by inhalation pharmacotherapy. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12458154     DOI: 10.1016/s0169-409x(02)00161-8

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  20 in total

1.  Linking increased airway hydration, ciliary beating, and mucociliary clearance through ENaC inhibition.

Authors:  Annika B M Åstrand; Martin Hemmerling; James Root; Cecilia Wingren; Jelena Pesic; Edvin Johansson; Alaina L Garland; Arunava Ghosh; Robert Tarran
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-10-31       Impact factor: 5.464

2.  Overnight delivery of hypertonic saline by nasal cannula aerosol for cystic fibrosis.

Authors:  Timothy E Corcoran; Joseph E Godovchik; Karl H Donn; David R Busick; Jennifer Goralski; Landon W Locke; Matthew R Markovetz; Michael M Myerburg; Ashok Muthukrishnan; Lawrence Weber; Ryan T Lacy; Joseph M Pilewski
Journal:  Pediatr Pulmonol       Date:  2017-07-24

3.  ENaC-mediated effects assessed by MRI in a rat model of hypertonic saline-induced lung hydration.

Authors:  F-X Blé; C Cannet; S Collingwood; H Danahay; N Beckmann
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

4.  Influence of Inhaled Amiloride on Lung Fluid Clearance in Response to Normobaric Hypoxia in Healthy Individuals.

Authors:  Courtney M Wheatley; Sarah E Baker; Bryan J Taylor; Manda L Keller-Ross; Steven C Chase; Alex R Carlson; Robert J Wentz; Eric M Snyder; Bruce D Johnson
Journal:  High Alt Med Biol       Date:  2017-09-06       Impact factor: 1.981

5.  NVP-QBE170: an inhaled blocker of the epithelial sodium channel with a reduced potential to induce hyperkalaemia.

Authors:  K J Coote; D Paisley; S Czarnecki; M Tweed; H Watson; A Young; R Sugar; M Vyas; N J Smith; U Baettig; P J Groot-Kormelink; M Gosling; R Lock; B Ethell; G Williams; A Schumacher; J Harris; W M Abraham; J Sabater; C T Poll; T Faller; S P Collingwood; H Danahay
Journal:  Br J Pharmacol       Date:  2015-04-23       Impact factor: 8.739

6.  Defining an inhibitory domain in the gamma subunit of the epithelial sodium channel.

Authors:  Christopher J Passero; Marcelo D Carattino; Ossama B Kashlan; Mike M Myerburg; Rebecca P Hughey; Thomas R Kleyman
Journal:  Am J Physiol Renal Physiol       Date:  2010-07-14

7.  Combined inhaled salbutamol and mannitol therapy for mucus hyper-secretion in pulmonary diseases.

Authors:  Hui Xin Ong; Daniela Traini; Giulia Ballerin; Lucy Morgan; Lachlan Buddle; Santo Scalia; Paul M Young
Journal:  AAPS J       Date:  2014-01-16       Impact factor: 4.009

8.  Airway responses to aerosolized brevetoxins in an animal model of asthma.

Authors:  William M Abraham; Andrea J Bourdelais; Juan R Sabater; Ashfaq Ahmed; Troy A Lee; Irakli Serebriakov; Daniel G Baden
Journal:  Am J Respir Crit Care Med       Date:  2004-09-24       Impact factor: 21.405

9.  Absorptive clearance of DTPA as an aerosol-based biomarker in the cystic fibrosis airway.

Authors:  T E Corcoran; K M Thomas; M M Myerburg; A Muthukrishnan; L Weber; R Frizzell; J M Pilewski
Journal:  Eur Respir J       Date:  2009-08-28       Impact factor: 16.671

10.  Evaluation of a SPLUNC1-derived peptide for the treatment of cystic fibrosis lung disease.

Authors:  Shawn T Terryah; Robert C Fellner; Saira Ahmad; Patrick J Moore; Boris Reidel; Juliana I Sesma; Christine S Kim; Alaina L Garland; David W Scott; Juan R Sabater; Jerome Carpenter; Scott H Randell; Mehmet Kesimer; William M Abraham; William J Arendshorst; Robert Tarran
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-10-05       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.